Dogan Taskent – Board Member, Swiss Chamber of Commerce, Turkey

05.10.2021
Dogan Taskent, board member of the Swiss Chamber of Commerce in Turkey, highlights Turkey’s successful response to the COVID-19 pandemic, how the local R&D ecosystem collaborated, often for free, to develop vaccines and treatments, one of which is currently in phase III clinical trials. In addition, Taskent analyzes the Turkish industry’s capabilities in biosimilars, and how it is providing “world class” quality pharmaceuticals at a reduced price.  
Companies should consider going beyond and investing in R&D localization in Turkey; they will be surprised by the potential
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Register
Already a member? Sign In
Tags:
Turkey, Swiss CHamber, Chamber of Commerce, Association, Investment, R&D, Manufacturing

Related Interviews

Umut Ağyüz – Founder & CEO, Genz Biotechnology

Genz Biotechnology is a biotech startup working on novel diagnostic testing solutions. Its founder and CEO, Umut Ağyüz, explains the origins of the company, the big opportunities that have arisen…

Souheil A ElHakim – CEO, Bıçakcılar

Bıçakcılar is one of Turkey’s largest medical technology companies, selling disposables and focusing on the operating room, any hospital’s most profitable part. Souheil A. ElHakim, the company’s CEO, reflects on…

Demet Eryilmaz – General Manager Turkey, Queisser

Queisser Pharma is a German company focused on the OTC market through food supplements and medical devices. Its general manager for Turkey, Demet Eryilmaz, tells the “special” story of its…

Related Articles

Turkey / Biosimilars on the Rise

With an already well-established manufacturing industry for pharmaceuticals, Turkey has been aiming to move with global trends and invest in biologics production, specifically in biosimilars.   The share of biotechnological…

Turkey / Can It Become a True Clinical Trials Hub?

Becoming the clinical trials country leader in the region has been set as a primary goal for Turkey’s pharma industry to achieve global competitiveness. The government’s strategy is to increase…

Turkey / GEN: From Niche Distributor to Public Company

Few Turkish companies are experiencing such a transformational moment as GEN. In 2021 alone, the Ankara-based organization made its public debut on the Istanbul Stock Exchange and signed an exclusive…

Latest Report

Switzerland Pharma Report June 2021

Related Content

Turkey
Swiss CHamber
Chamber of Commerce
Association
Investment
R&D
Manufacturing